In this demanding market, we are thrilled to be able to provide our customers with a clinically proven, competitive option for hair removal
Yokneam, Israel (Vocus) April 14, 2010
Lumenis Ltd., a global leader in developing, manufacturing and distributing a broad range of high-end medical lasers and sophisticated energy delivery equipment for surgical, ophthalmic and aesthetic applications, today announced that it is scheduled to present at the 30th Annual American Society for Laser Medicine and Surgery (ASLMS) meeting in Phoenix, AZ. The company will proudly unveil its first clinical study displaying the speed and comfort of its new LightSheer Duet laser for hair removal. Thought leaders will also discuss the company’s UltraPulse Encore, a cutting edge skin treatment for superficial to deep mature burn scars, during two scientific sessions.
Scientific Sessions Showcase Innovation In Medical Laser Applications
Several emerging industry leaders in the field of medical laser applications are scheduled to present throughout the meeting to discuss both the UltraPulse Encore and LightSheer Duet. Highlights to include:
- Friday, April 16: Deep Dermis Remodelation with a Micro Ablative Fractional Carbon Dioxide Laser in a Vectorial Pass Technique; Guilherme Almeida, MD
- Friday, April 16: Two-Years Treatment to Brazilian Patients with Dark Skin by Deep Fractional Carbon Dioxide Laser (TotalFX) Using Tridimensional Documentation; Guilherme Almeida, MD
- Saturday, April 17: Scar Reduction; Jill Waibel, MD
- Sunday, April 18: Side-By-Side Comparison of High-Fluence and Low Fluence Diode Laser in Axillary Hair Removal; Shlomit Halachmi, MD
Carbon Dioxide Laser Platforms Expand Burn Treatment Solutions
The advent of the new Lumenis AcuPulse Aesthetic SuperPulsed CO2 platform, combined with the UltraPulse TotalFX system, provides a comprehensive solution for skin damage. It is now being used as first line offense around the world for acute and mature scarring.
To exemplify the laser’s wide-ranging capability, clinical dermatologist Dr. Guilherme Almeida will present results of two pivotal studies. One study will show TotalFX success on dark skinned patients, while the other highlights deep dermal collagen remodeling by way of the Vectorial Pass Technique.
Dermatologist Dr. Jill Waibel will also be presenting on her achievements with burn scars. This follows her successful treatments on the 22-year old Berns triplets, who suffered severe burns from a house fire they experienced as small children. Dr.Waibel was one of the first to use a deeper resurfacing technique to penetrate layers of skin to reach the collagen below and stimulate growth, bringing about dramatic results for the girls.
LightSheer Duet Exceeds Patient Expectations
After initial success, the LightSheer Duet has a new, redesigned disposable insert to provide users with a faster and simplified option during hair removal treatment. Data shows exceeded comfort for patients and a lower price point due to the laser’s rapid speed.
“In this demanding market, we are thrilled to be able to provide our customers with a clinically proven, competitive option for hair removal,” said Mr. Dov Ofer, CEO of Lumenis.
The new data outlining the LightSheer Duet’s efficacy, which was compiled by Dr. Shlomit Halachmi and Dr. Moshe Lapidoth (Rabin Medical Center, Israel), will be presented by Dr. Halachmi on Sunday, April 18.
The M22 Platform Provides Unsurpassed Ease Of Use
Rounding out the Lumenis display at ASLMS is the new M22 multi-application platform which allows treatment of multiple skin conditions. The streamlined tabletop is user-friendly, has multilingual capability, touch screen interface and hundreds of presets. Physicians can even treat a variety of skin types by controlling each pulse shape.
“Lumenis IPL systems have always been the gold standard of IPL’s. The M22 is Lumenis’ latest advancement in IPL technology, offering efficacy that is second to none, improved patient comfort, speed, versatility and reliability that Lumenis is known for. This translates into increased patient satisfaction and increased profitability,” said Dr. Mitchel P. Goldman, Founder and Medical Director of Goldman, Butterwick, Keel Cosmetic Laser Dermatology and Volunteer Clinical Professor of Dermatology/Medicine at UC San Diego.
To see the comprehensive product line or for a complete listing of speaker presentations, please visit Lumenis at booth #904 at the ASLMS.
Lumenis, one of the world’s largest medical laser companies, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has nearly 250 patents, over 75 FDA clearances, an installed base of over 80,000 systems and presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light which is the basis of our technologies used to enhance life. For more information about Lumenis and its products, please go to: http://www.lumenis.com
Director of Corporate Communications
Lumenis®, the Lumenis logo, AcuPulse, LightSheer, LightSheer Duet, LumeProbe, M22, Novus, Novus Spectra, Polyscope, Selecta, Slimline and SurgiTouch are trademarks and service marks of Lumenis Ltd. and may be registered in certain jurisdictions
Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled “Risk Factors”, as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.